Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
Figure 3
Sitagliptin use does not adversely affect renal graft function (as measured by serum creatinine and estimated GFR), liver function (as measured by serum AST and ALT), or immunosuppressant levels. (a) Serum creatinine. (b) Estimated GFR (eGFR). (c) Serum AST and ALT levels (). (d) Serum tacrolimus trough levels (). (e) Serum sirolimus trough levels (). Data shown as mean ± SD. SGT = sitagliptin.
